Monthly Cost Breakdown: Planning Your Treatment Budget
Understanding Which Is Better Mounjaro or Wegovy for Your Budget
When evaluating which is better between Mounjaro or Wegovy, the monthly cost structure plays a crucial role in your decision. Both treatments require a gradual dose escalation over 16 weeks, but their pricing trajectories differ significantly. Wegovy follows a structured cost progression starting at £79.99 for the initial 0.25mg dose, designed to help your body adjust to this GLP-1 receptor agonist gradually. The predictable monthly increases allow you to budget effectively for your weight management journey alongside a reduced-calorie diet and increased physical activity.
Mounjaro, as a dual GIP and GLP-1 receptor agonist, operates on a different pricing model that may influence your choice between these prescription-only medicines. Understanding these cost differences helps determine which treatment aligns better with your financial planning. Both medications are available through our GPhC-registered pharmacy (#9012878), ensuring you receive genuine, properly stored medication regardless of your choice.
Wegovy Monthly Cost Progression: Complete UK Pricing Guide
Wegovy's dose escalation follows a carefully structured 16-week programme, with each monthly cost increase reflecting the higher active ingredient content. Your journey begins at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing to £94.99 for 0.5mg (weeks 5-8), then £99.99 for 1mg (weeks 9-12). The penultimate step costs £139.99 for 1.7mg (weeks 13-16), before reaching the maintenance dose of 2.4mg at £209.99 monthly from week 17 onwards. New customers benefit from our FIRST40 discount code, whilst returning customers use DOSE25, both applied at checkout to reach these final prices.
Annual cost planning becomes straightforward once you reach the maintenance dose, with 2.4mg costing £209.99 monthly. This translates to approximately £2,519.88 annually for ongoing treatment, though bundle options like our Ultimate Stability Trio (three 2.4mg pens for £649.99) can provide convenience benefits. The predictable monthly cost structure helps you budget effectively compared to the variable pricing often seen with private weight management programmes.
Clinical Evidence: Which Is Better Mounjaro or Wegovy Based on Trial Data
When comparing which is better between Mounjaro or Wegovy, clinical trial evidence provides valuable insights, though direct head-to-head comparisons remain limited. In the STEP clinical trials, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 trial demonstrated sustained weight loss of approximately 15.2% over two years, supporting Wegovy's long-term effectiveness.
Mounjaro's SURMOUNT trials showed different results in separate study populations, making direct percentage comparisons inappropriate due to varying trial designs and participant characteristics. Both treatments demonstrated cardiovascular benefits in their respective studies, with Wegovy's SELECT trial showing a 20% reduction in major cardiovascular events. Your prescriber can help determine which treatment's clinical profile aligns better with your individual health circumstances and weight management goals.
How Wegovy Works: GLP-1 Receptor Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces when you eat. This prescription-only medicine works by binding to GLP-1 receptors in your brain's appetite control centres, helping reduce feelings of hunger and increase satiety after smaller meals. The mechanism may also slow gastric emptying, meaning food stays in your stomach longer, contributing to prolonged feelings of fullness. Unlike Mounjaro's dual-receptor approach targeting both GIP and GLP-1 pathways, Wegovy focuses specifically on GLP-1 receptor activation. This targeted approach has been extensively studied across multiple clinical trials, establishing its effectiveness when used alongside lifestyle modifications for sustainable weight management.
Ordering Process: From Assessment to Delivery
Starting your Wegovy journey through EverydayMeds involves a streamlined three-step process designed for convenience and safety. First, complete our 3-minute online clinical assessment, providing essential medical history and current health information for prescriber review. Our qualified prescribers then review your assessment within three working days (or 24 hours with our express service), ensuring Wegovy is clinically appropriate for your circumstances. Once approved, your medication ships via next-day delivery using our temperature-controlled cold-chain system, maintaining the medication's integrity from our GPhC-registered pharmacy (#9012878) to your door. Each shipment includes comprehensive administration guidance and our clinical support contact details for ongoing assistance throughout your treatment.
Storage and Practical Considerations for Long-term Use
Wegovy requires refrigerated storage at 2-8°C before first use, but offers significant practical advantages once removed from refrigeration. Each FlexTouch pen maintains its potency for up to six weeks at room temperature below 30°C, compared to Mounjaro's 21-day limit, making Wegovy more travel-friendly for business trips or holidays. The pre-filled FlexTouch pen design simplifies weekly administration, with clear dose indicators and an automatic needle cover for safety. Dose escalation follows a mandatory progression schedule that cannot be accelerated, ensuring your body adapts gradually to increasing semaglutide levels. This structured approach helps minimise potential gastrointestinal side effects whilst maximising therapeutic benefits when combined with dietary and exercise modifications.
Long-term Financial Planning: Which Is Better Mounjaro or Wegovy for Ongoing Costs
Determining which is better between Mounjaro or Wegovy requires careful consideration of long-term financial commitments beyond the initial months. Wegovy's maintenance dose cost of £209.99 monthly provides predictable budgeting for ongoing treatment, essential since clinical evidence suggests weight regain occurs when treatment stops. The STEP 1 extension study showed patients regained approximately two-thirds of lost weight within one year of discontinuing treatment, emphasising that weight management represents a long-term commitment rather than a temporary intervention.
Bundle purchasing options can help manage cash flow whilst ensuring treatment continuity, with our consistency bundles offering two months' supply and step-up bundles covering multiple escalation phases. Returning customers benefit from our DOSE25 discount code, maintaining competitive pricing throughout extended treatment periods. When weighing which is better between these treatments, consider not just the monthly costs but also storage convenience, dosing flexibility, and your prescriber's clinical recommendation based on your individual health profile.
Expert Guidance: Making Your Treatment Choice
Both Wegovy and Mounjaro are available from EverydayMeds, with our prescribers helping determine which treatment aligns best with your clinical needs and lifestyle preferences. The decision between these prescription-only medicines should consider factors beyond cost, including your medical history, current medications, and weight management goals. Our clinical team can discuss how each treatment's mechanism of action might suit your individual circumstances, ensuring you make an informed choice. Whether you select Wegovy's proven GLP-1 approach or Mounjaro's dual-receptor targeting, our ongoing support includes clinical monitoring and practical guidance throughout your weight management journey. Remember that both treatments require commitment to dietary changes and increased physical activity for optimal results, with our team providing resources to support these lifestyle modifications alongside your chosen medication.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
